Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study

Anticancer Research

Volumn 27, Issue 3 B, 2007, Pages 1527-1530

  Mustea, Alexander ^c   Sehouli, Jalid ^c   Fabjani, Gerhild ^a   Koensgen, Dominique ^c   Mobus V ^b   Braicu, Elena Ioana ^c   Pirvulescu, Cristina ^c   Thomas, Anke ^c   Tong, Dan ^a   Zeillinger, Robert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Eye Hospital   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

EGFR; Ovarian cancer; Pyrosequencing

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE MUTATION; GENE SEGREGATION; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; OVARY CARCINOMA; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; MUTATION, MISSENSE; OVARIAN NEOPLASMS; PILOT PROJECTS; PLATINUM COMPOUNDS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION; SURVIVAL;

EID: 34249340498     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Landis SH, Murray T and Bolden S: Cancer statistics: CA Cancer J Clin 8: 49-54, 1999.
2. Chang J, Bridgewater J and Gore M: Non-surgical aspects of ovarian cancer. Lancet 343: 335-341, 1994.
3. Lichtenegger W, Sehouli J, Buchmann E, Karajanev C and Weidemann H: Operative results after primary and secondary debulking-operations in advanced ovarian cancer (AOC). J Obstet Gynaecol Res 24: 447-451, 1998.
4. Sehouli J, Stengel D, Elling D, Ortmann O, Blohmer J, Riess H and Lichtenegger W: First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study. Gynecol Oncol 85: 321-326, 2002.
5. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J and Dmitrovsky E: Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor a is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3: 515-522, 1997.
6. Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M and Franklin WA: Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 41: 29-42, 2003.
7. Skirnisdóttir I et al: The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer 11: 119-129, 2001.
8. Fisher-Colbrie J et al: EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 17: 613-619, 1997.
9. Bast RC et al: Coexpression of the HER-2 gene product, p185HER-2 and epidermal growth factor receptor, p17EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma 17: 313-321, 1998.
10. Harlozinska A et al: Epidermal growth factor receptor and c-erbB-2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms. Tumour Biol 19: 364-373, 1998.
11. Ilekis JV et al: Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 66: 250-254, 1997.
12. Ranson M: ZD 1839 (Iressa): For more than just non-small cell lung cancer. Oncologist 7: 16-24, 2002.
13. Sehouli J, Wagner U, du Bois A et al: A phase II study of the AGO Ovarian cancer study group (AGO-Ovar 2.6): ZD1839 in combination with tamoxifen in refractory ovarian cancer. Int J Gynecol Cancer 15: 51-80, 2005.
14. Lynch TJ, Bell DW, Sordella R et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
15. Paez JG, Janne PA, Lee JC et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
16. Pao W, Miller V, Zakowski M et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
17. Sehouli J, Konsgen D, Mustea A, Oskay-Ozcelik G, Katsaros I, Weidemann H and Lichtenegger W: "IMO" - intraoperative mapping of ovarian cancer. Zentralbl Gynaekol 125: 129-135, 2003.
18. Sehouli J, Stengel D, Oskay G, Camara O, Hindenburg HJ, Klare P, Blohmer J, Heinrich G, EUing D, Ledwon P and Lichtenegger W: A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Ann Oncol 13: 1749-1755, 2002.
19. Cohen MH, Williams GA, Sridhara R et al: United States Food and Drug Administration drug approval summary: gefitinib (ZD1839: Iressa): tablets. Clin Cancer Res 10: 1212-1218, 2004.
20. Sordella R, Bell DW, Haber DA and Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167, 2004.
21. Finkler N et al: Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc Am Soc Clin Oncol 21: 208, 2001.
22. Yang SH, Mechanic LE, Yang P et al: Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in nonsmall cell lung cancer. Clin Cancer Res 11: 2106-2110, 2005.
23. Huang SF, Liu HP, Li LH et al: High frequency of epidermal growth factor receptor mutations with complex patterns in nonsmall cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10: 8195-8203, 2004.
24. Han SW, Kim TY, Hwang PG et al: Predictive and prognostic impact of epidermal growth factor receptor mutation in nonsmall cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493-2501, 2005.
25. Kosaka T, Yatabe Y, Endoh H et al: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-8923, 2004.